Rabies immune globulin purified - Grifols

Drug Profile

Rabies immune globulin purified - Grifols

Alternative Names: RIG-C

Latest Information Update: 17 Sep 2014

Price : $50

At a glance

  • Originator Grifols
  • Class Antivirals; Immunoglobulins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Rabies

Most Recent Events

  • 01 May 2014 Grifols completes a phase I trial in Rabies (Prevention) in USA (NCT02139657)
  • 01 Mar 2014 Phase-I clinical trials in Rabies (Prevention) in USA (IM) (NCT02139657)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top